,133,134,135,136 The galectin-3 inhibitor belapectin (GR-MD-02) was reported to reduce liver fibrosis in NASH patients in a phase 2 study (NCT02421094). This evidence concerns the gene LGALS3 and metabolic dysfunction-associated steatohepatitis.